INGELHEIM, Germany & INDIANAPOLIS--(BUSINESS WIRE)--EX US, UK and UAE Medical Media Only. Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced results of a 24-week open label arm ...
Boehringer Ingelheim Pharmaceuticals and Eli Lilly announced the FDA has approved a supplemental new drug application for Tradjenta tablets for use as add-on therapy to insulin. Tradjenta is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback